The stock's recent strength suggests investors are becoming more confident
In the uncertain terrain between innovation and overreach, Butterfly Network finds itself at a crossroads familiar to many companies that dare to reimagine entrenched industries. Trading at $4.24 in May 2026, the maker of handheld ultrasound devices has delivered remarkable year-long gains even as its single-day declines unsettle the faithful, embodying the perennial tension between a technology's promise and the market's patience. A landmark partnership with Midjourney lends credibility to the vision, yet competing valuations — one pointing nearly 35% higher, another suggesting the stock is worth less than half its current price — remind us that belief and evidence are not always the same currency. The question the market is quietly asking is not merely what Butterfly Network is worth today, but whether the future it is selling will arrive on the schedule its price already assumes.
- A single-day drop of 6.8% and a weekly decline of 11.5% have rattled short-term holders even as the stock sits 86.8% higher than it was a year ago, creating a disorienting whipsaw that forces investors to choose which timeframe to trust.
- The valuation divide is not a matter of rounding errors — one credible bearish model places fair value at $1.80, meaning the stock could be more than twice as expensive as the underlying business justifies under conservative assumptions.
- A five-year exclusive deal with Midjourney — $15 million upfront, $10 million in annual fees, with milestone and revenue-sharing potential — has injected real-world validation into what was previously a story built largely on technological possibility.
- The entire debate pivots on adoption: whether hospitals will deploy handheld ultrasound at scale, whether the Compass AI platform becomes indispensable, and whether chip-embedded ultrasound can outcompete entrenched alternatives.
- With $102.9 million in annual revenue, the company is neither too small to dismiss nor large enough to be insulated from the consequences of slower-than-expected market penetration, leaving the stock acutely sensitive to every signal about commercial traction.
Butterfly Network's stock tells two stories at once, and the market has not yet decided which one is true. Shares closed at $4.24 on a Tuesday in May, down sharply on the day and over the week — yet the same stock has risen more than 86% over the past year. That contradiction is not noise. It is the sound of investors actively renegotiating what the company is worth.
The business itself is tangible enough: handheld ultrasound devices that could extend medical imaging beyond the walls of hospitals, backed by $102.9 million in annual revenue. Analysts on average see the stock climbing to $5.69, a reasonable-sounding 34% upside. But that consensus conceals a more serious disagreement. The most rigorous bearish case arrives at $1.80 per share — not through pessimism about the technology, but through disciplined cash flow modeling that assumes adoption simply takes longer than bulls expect. At today's price, that framework implies investors have gotten ahead of themselves by more than a factor of two.
The partnership with Midjourney, announced in late 2025, is the event bulls point to most readily. Butterfly Network's subsidiary secured a five-year exclusive agreement granting the AI image-generation company access to its semiconductor-based ultrasound technology, with $15 million paid upfront and $10 million in annual license fees to follow. For those who believe in the technology, a major AI company committing real capital is the kind of third-party endorsement that separates genuine breakthroughs from well-funded experiments.
Skeptics read the same deal more cautiously. One partnership, however meaningful, does not confirm a market. The deeper questions remain open: Will Compass AI, the company's image-analysis platform, become essential infrastructure? Will the chip-based approach prove durable against competing solutions? Will adoption move fast enough to justify a price that already leans into an optimistic future?
What makes Butterfly Network worth watching is precisely that both narratives remain plausible. The technology is real, the revenue is real, and the Midjourney deal is real. But so is the gap between what the stock costs today and what a careful, conservative analysis says it should cost. The coming months — measured in adoption curves, platform traction, and partnership outcomes — will determine whether $4.24 looks, in hindsight, like an entry point or a warning.
Butterfly Network's stock is caught between two competing stories about what the company is worth. On a Tuesday in May, shares closed at $4.24, down 6.8% in a single day and 11.5% over the week. Yet zoom out to the longer view, and the picture inverts: the stock has climbed 25.4% in three months and 86.8% over the past year. This whipsaw—sharp declines punctuating a sustained rally—has forced investors to confront a fundamental question: Is the market pricing in real progress, or has enthusiasm outrun the underlying business?
Butterfly Network makes handheld ultrasound devices, a technology that could reshape how medical imaging gets done outside hospitals and clinics. The company generated $102.9 million in annual revenue, a meaningful figure for a medical device maker still in growth mode. Wall Street analysts, on average, see the stock heading to $5.69—a modest 34% upside from current levels. But that consensus masks a deeper disagreement. The most prominent bearish case values the company at $1.80 per share, implying the stock is 135.6% overvalued at today's price. That's not a minor quibble. It's a claim that investors have gotten ahead of themselves by more than a factor of two.
The bull case rests partly on a partnership announced in November 2025. Butterfly Network's subsidiary signed a five-year agreement with Midjourney, the AI image-generation company, for exclusive access to semiconductor-based ultrasound technology. The deal came with a $15 million upfront payment, $10 million in annual license fees, and the potential for additional milestone payments and revenue sharing. For believers in the technology, this was validation—a major tech company betting real money on the idea that ultrasound could be miniaturized and embedded into chips. For skeptics, it was a single data point in an unproven market.
The valuation gap hinges on assumptions about adoption. Will hospitals and clinics actually deploy handheld ultrasound devices at scale? Will Compass AI, Butterfly Network's artificial intelligence platform for image analysis, become essential infrastructure? Will the semiconductor-based approach prove superior to existing alternatives? The bearish model assumes conservative answers to all three questions, then applies a disciplined cash flow framework to arrive at $1.80. The model bakes in solid revenue growth and healthy profit margins—it's not a doomsday scenario. It's simply a more skeptical read of how quickly the market will move.
What makes this moment worth watching is that both narratives could be right, depending on what happens next. The stock's recent strength suggests investors are becoming more confident in Butterfly Network's long-term potential. The Midjourney deal is real. The technology is real. The market for portable ultrasound is real. But confidence and reality are not the same thing. A company can have a breakthrough product and still trade at a price that assumes too much, too soon.
For investors trying to decide whether to buy, hold, or sell, the honest answer is that the story is still being written. The near-term volatility—the 6.8% drops and the 25% rallies—reflects genuine uncertainty about which narrative will prove correct. The company's current revenue of $102.9 million is substantial enough to matter, but not so large that it can't be disrupted by faster or slower adoption than expected. The Midjourney partnership is a real endorsement, but one partnership does not a market make. What comes next—whether adoption accelerates, whether Compass AI gains traction, whether the semiconductor approach scales—will determine whether $4.24 looks like a bargain or a peak.
Citações Notáveis
The current share price sits well above the narrative's fair value, implying investors are already paying a premium to the cash flow and profitability profile that underpin this scenario— Bearish valuation analysis
A Conversa do Hearth Outra perspectiva sobre a história
Why does a handheld ultrasound company matter enough to warrant this kind of valuation debate?
Because if it works at scale, it changes the economics of medical imaging. Ultrasound machines are expensive, require trained technicians, and are mostly stuck in hospitals. If you can put that capability into a device the size of a pen, you open up clinics, ambulances, remote areas. That's a real market shift.
But the stock is down 6.8% in one day and up 86.8% in a year. How do you make sense of that contradiction?
The long-term move reflects growing belief in the technology and the Midjourney partnership. The short-term swings are investors testing whether that belief is priced in fairly. The bearish case says it's not—that $4.24 assumes too much future success. The bulls say the partnership proves the technology works and adoption is coming.
The bearish case values the company at $1.80. That's a massive gap from $4.24. How does that happen?
It comes down to how conservative you are about adoption rates and profit margins. The bearish model doesn't say the company will fail. It says revenue will grow, margins will be healthy, but not as fast or as wide as the current price assumes. When you discount those cash flows back to today, you get $1.80.
Is the Midjourney deal a game-changer or just noise?
It's real validation from a major tech company, which matters. But one partnership doesn't prove the market will adopt at scale. It's a signal, not a guarantee. The question is whether other companies and institutions follow Midjourney's lead.
What would make the bearish case wrong?
If ultrasound-on-chip adoption accelerates faster than expected, if Compass AI becomes essential infrastructure in hospitals, if the semiconductor approach proves superior to alternatives. Any of those could justify a higher valuation. Right now, the market is betting on some combination of those things. The bearish case is betting they won't materialize as quickly.
So what should an investor do?
Test the assumptions yourself. What adoption rate seems realistic? How fast will margins expand? What's the real competitive advantage? The stock's volatility suggests the market hasn't settled on answers yet. That's when homework matters most.